AU2015217293A1 - Compositions and methods for treating diabetes and liver diseases - Google Patents

Compositions and methods for treating diabetes and liver diseases Download PDF

Info

Publication number
AU2015217293A1
AU2015217293A1 AU2015217293A AU2015217293A AU2015217293A1 AU 2015217293 A1 AU2015217293 A1 AU 2015217293A1 AU 2015217293 A AU2015217293 A AU 2015217293A AU 2015217293 A AU2015217293 A AU 2015217293A AU 2015217293 A1 AU2015217293 A1 AU 2015217293A1
Authority
AU
Australia
Prior art keywords
group
optionally substituted
hydroxy
solithromycin
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015217293A
Other languages
English (en)
Inventor
Prabhavathi Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of AU2015217293A1 publication Critical patent/AU2015217293A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2015217293A 2014-02-14 2015-02-11 Compositions and methods for treating diabetes and liver diseases Abandoned AU2015217293A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461939961P 2014-02-14 2014-02-14
US61/939,961 2014-02-14
US201461984225P 2014-04-25 2014-04-25
US61/984,225 2014-04-25
US201462086911P 2014-12-03 2014-12-03
US62/086,911 2014-12-03
PCT/US2015/015353 WO2015123256A1 (en) 2014-02-14 2015-02-11 Compositions and methods for treating diabetes and liver diseases

Publications (1)

Publication Number Publication Date
AU2015217293A1 true AU2015217293A1 (en) 2016-09-01

Family

ID=53800574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015217293A Abandoned AU2015217293A1 (en) 2014-02-14 2015-02-11 Compositions and methods for treating diabetes and liver diseases

Country Status (12)

Country Link
US (1) US20170165286A1 (enExample)
EP (1) EP3105234A4 (enExample)
JP (2) JP6553067B2 (enExample)
KR (1) KR20160113307A (enExample)
CN (1) CN106132969A (enExample)
AU (1) AU2015217293A1 (enExample)
CA (1) CA2939076A1 (enExample)
IL (1) IL247152A0 (enExample)
MX (1) MX2016010447A (enExample)
RU (1) RU2016133471A (enExample)
WO (1) WO2015123256A1 (enExample)
ZA (1) ZA201606199B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CA2868262A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
RU2018128393A (ru) 2012-09-17 2019-03-14 Мадригал Фармасьютикалз, Инк. Способ синтеза аналогов гормонов щитовидной железы и их полиморфов
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
MX394463B (es) 2016-10-18 2025-03-19 Madrigal Pharmaceuticals Inc Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta.
EP3541395A4 (en) * 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
CA2292359C (en) * 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2897154B1 (fr) * 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
WO2007129646A1 (ja) * 2006-05-01 2007-11-15 Taisho Pharmaceutical Co., Ltd. マクロライド誘導体
JP5025249B2 (ja) * 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
JP5150740B2 (ja) * 2011-01-21 2013-02-27 株式会社小松製作所 作業車両
AU2012303693B2 (en) * 2011-08-30 2014-07-03 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
US9078975B2 (en) * 2011-09-30 2015-07-14 Becton Dickinson France, S.A.S. Syringe having pivoting arm plunger rod

Also Published As

Publication number Publication date
ZA201606199B (en) 2020-01-29
KR20160113307A (ko) 2016-09-28
WO2015123256A1 (en) 2015-08-20
MX2016010447A (es) 2016-12-20
RU2016133471A (ru) 2018-03-19
RU2016133471A3 (enExample) 2018-09-24
IL247152A0 (en) 2016-09-29
CA2939076A1 (en) 2015-08-20
US20170165286A1 (en) 2017-06-15
EP3105234A4 (en) 2017-11-08
EP3105234A1 (en) 2016-12-21
JP6553067B2 (ja) 2019-07-31
JP2019189639A (ja) 2019-10-31
CN106132969A (zh) 2016-11-16
JP2017505785A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
US20170165286A1 (en) Compositions and methods for treating diabetes and liver diseases
AU2018203357B2 (en) New methods
US11419878B2 (en) Medicine obtained by combining FXR agonist and ARB
US20050245609A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
UA123700C2 (uk) Композиції і способи інгібування активності аргінази
KR20170095894A (ko) 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
KR20150050595A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
WO2020006199A2 (en) Methods and agents for modulating inflammation
US8912167B2 (en) Heparin-based compositions and methods for the inhibition of metastasis
JP6908936B2 (ja) セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
HK1231075A1 (en) Compositions and methods for treating diabetes and liver diseases
CN107427480A (zh) 用于预防和/或治疗脂肪性肝炎的脂肪酸酰胺
US9937194B1 (en) Compounds and methods for treating inflammatory diseases
JP2022514672A (ja) ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
US20240238256A1 (en) Nitazoxanide in the treatment of sepsis
WO2007081061A1 (ja) 神経因性疼痛治療剤
JP6551671B2 (ja) アルツハイマー治療薬
CN118453879A (zh) 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用
KR20050059293A (ko) 배변 기능 장애의 치료 및/또는 예방제
HK1260722A1 (en) Medicine obtained by combining fxr agonist and arb
HK40001613B (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted